Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...

AKeem Rollins, MPH, doesn’t really “clock out.” As a PrEP (Pre-Exposure Prophylaxis) Navigator at MetroHealth, he spends his days — alongside two other PrEP Navigators — helping people get the sexual ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...

The U.S. Food and Drug Administration (FDA) has approved the sale of a new injectable medication that stops the spread of HIV. Lenacapavir (Yeztugo) is a type of injectable HIV pre-exposure ...

Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice-yearly option for the prevention of HIV ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid ...

A twice yearly injection that is highly effective in preventing HIV transmission could dramatically reduce infections and save lives — if the people who would most benefit from the drug can obtain it, ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

Editor’s note: “Behind the News” is the product of Sun staff assisted by the Sun’s AI lab, which includes a variety of tools such as Anthropic’s Claude, Perplexity AI, Google Gemini and ChatGPT.